Larvol Delta - In-Q1-2026-the-company-ended-development-of-avoralstat-a-plasma-kallikrein-inhibitor-for-the-treatment-of-diabetic-macular-edema-to-focus-the-pipeline-on-rare-diseases

avoralstat (BCX4161) - BioCryst Pharmaceuticals

https://www.globenewswire.com/news-release/2026/05/06/3288643/29446/en/biocryst-reports-first-quarter-2026-financial-results-and-provides-business-update.html

May 6, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next